Based on the theoretical framework of the core concepts of the Inner Canon of Yellow Emperor （《黄帝内经》）， this paper systematically elucidates the connotations of the mind and qi in traditional Chinese medicine and their interrelationship， and proposes the method of regulating qi and calming the mind. It emphasizes that the mind represents the outward manifestation of life phenomena and their underlying laws， while qi encompasses both a material foundation and functional dynamics. Mind and qi are jointly expressed in life activities through observable manifestations. In clinical practice， image-based thinking should be adopted， integrating theories such as yin-yang， the five elements， and essence-qi， to construct a diagnostic and therapeutic model of "manifestation-mechanism-syndrome-treatment". Treatment should be carried out from four aspects which include regulating body and constitution， recti-fying qi movement， calming the mind changes， and stabilizing emotional states. Moreover， it is necessary to take into account the coordinated regulation of both body and mind， as well as the maintenance of dynamic balance， to select appropriate formulas and medications.

Based on the theoretical framework of the core concepts of the Inner Canon of Yellow Emperor （《黄帝内经》）， this paper systematically elucidates the connotations of the mind and qi in traditional Chinese medicine and their interrelationship， and proposes the method of regulating qi and calming the mind. It emphasizes that the mind represents the outward manifestation of life phenomena and their underlying laws， while qi encompasses both a material foundation and functional dynamics. Mind and qi are jointly expressed in life activities through observable manifestations. In clinical practice， image-based thinking should be adopted， integrating theories such as yin-yang， the five elements， and essence-qi， to construct a diagnostic and therapeutic model of "manifestation-mechanism-syndrome-treatment". Treatment should be carried out from four aspects which include regulating body and constitution， recti-fying qi movement， calming the mind changes， and stabilizing emotional states. Moreover， it is necessary to take into account the coordinated regulation of both body and mind， as well as the maintenance of dynamic balance， to select appropriate formulas and medications.

This paper summarizes Professor ZHAI Shuangqing's clinical experience in using metal and mineral medicines to treat mental disorders. Based on xiang thinking， the symptoms of mental disorders are classified into five categories， depression-xiang， wind-xiang， fire-xiang， phlegm-xiang， and deficiency-xiang， and the mechanisms of disease development are discussed accordingly. Metal and mineral medicines are key treatments for mental disorders， not only having the function of calming the mind but also promoting qi， stabilizing wind， expelling evil， and tonifying. In clinical practice， the emphasis is placed on harmonizing the disease and its symptoms. Based on self-developed prescription formulas， the appropriate metal and mineral medicines are selected according to the properties， flavors， meridian tropism， and actions of the medicines， as well as the xiang patterns of the mental disorder. For example， Attention Deficit Hyperactivity Disorder （ADHD） is treated by Modified Xiehuang Powder （泻黄散） with Sijunzi Decoction （四君子汤） and adding Fulonggan （Testudinis Carapax） and Longgu （Os Draconis）. Persistent insomnia is treated by combining a self-developed insomnia formula with Longgu （Os Draconis）， Hupo （Succinum）， and Cishi （Magnetitum）. Obsessive-compulsive disorder （OCD） is treated by combining a self-developed OCD formula with Longchi （Dens Draconis）， Qingmengshi （Fluoritum）， and Zheshi （Haematitum）. Epilepsy is treated by combining an anti-epilepsy decoction with Qingmengshi （Fluoritum）， Longchi （Dens Draconis）， and Shengtieluo （Ferrum Rudis）.

Objective To explore the safety of Yttrium-90 resin microsphere selective internal radiation therapy (⁹⁰Y-SIRT) on malignant liver tumors. Methods A retrospective analysis was conducted on 64 patients with malignant liver tumors who underwent ⁹⁰Y-SIRT from February 2023 to November 2024 at Weifang People’s Hospital. The clinical characteristics of the patients and the occurrence of adverse reactions after treatment were analyzed to assess the safety of ⁹⁰Y-SIRT. Results Among the 64 patients, there were 52 males (81.25%) and 12 females (18.75%); the average age was (56.29±11.08) years. Seven patients (10.94%) had tumors with maximum diameter of less than 5 cm, 38 patients (59.38%) had tumors with maximum diameter of 5-10 cm, and 19 patients (29.68%) had tumors with maximum diameter of greater than 10 cm. There were 47 cases (73.44%) of solitary lesions and 17 cases (26.56%) of multiple lesions; 53 cases (82.81%) were primary liver cancers and 11 cases (17.19%) were metastatic liver cancers. Of the 64 patients, 63 successfully completed the Technetium-99m macroaggregated albumin (^99mTc-MAA) perfusion test and received the ⁹⁰Y-SIRT; one patient received ⁹⁰Y-SIRT after the second ^99mTc-MAA perfusion test due to a work error. The most common adverse reactions included grade 1 alanine aminotransferase (ALT) elevation in 26 cases (40.62%) and grade 2 in 2 cases (9.37%), grade 1 aspartate aminotransferase (AST) elevation in 27 cases (42.18%) and grade 2 in 7 cases (10.93%); grade 1 nausea in 17 cases (26.56%) and grade 2 in 6 cases (9.37%); grade 1 abdominal pain in 12 cases (18.75%), grade 2 in 5 cases (7.81%), and grade 3 in 1 case (1.56%); grade 1 vomiting in 11 cases (17.18%), grade 2 in 5 cases (7.81%), and grade 3 in 1 case (1.56%). Conclusion The adverse reactions of ⁹⁰Y-SIRT for treating malignant liver tumors are mild, indicating good safety.

AIM: To investigate the association between HOXA1 and FOXF2 gene variants and genetic susceptibility in multigenerational families with exotropia, and to elucidate the molecular genetic etiological mechanisms of exotropia.METHODS:A total of 10 multigenerational families with a definitive history of exotropia were recruited from September 2023 to February 2025, comprising 165 members(87 exotropia patients and 78 normal controls). Detailed ophthalmological examinations were performed, family pedigrees were constructed, peripheral blood samples were collected, genomic DNA was extracted, and PCR amplification followed by Sanger sequencing were used to detect exons and flanking sequences of the HOXA1 and FOXF2 genes. Identified variants were subjected to pathogenicity classification and association analyses.RESULTS:Among the 10 families, 5 variant sites in HOXA1(c.218G>A, c.385C>T, c.496A>G, c.652T>C, c.874C>T)and 4 in FOXF2(c.102C>T, c.344G>A, c.576T>C, c.892A>G)were identified. The HOXA1 c.496A>G variant showed statistically significant differences between carrier and noncarrier in exotropia angle, exotropia type, stereoscopic vision, and parallax(all P<0.05). The age of onset of FOXF2 gene c.344G>A mutation carrier group was younger than that of the non-carrier group(t=3.55, P=0.004).CONCLUSION:HOXA1 and FOXF2 gene variants are significantly associated with genetic susceptibility to exotropia, particularly influencing age of onset and deviation angle, offering novel targets for molecular diagnosis and precision treatment of exotropia.

OBJECTIVE To explore comprehensive management and potential issues associated with long-term prescriptions medications of psychiatry， in order to provide a reference for the comprehensive management of long-term prescriptions of psychiatry in psychiatric hospitals and other medical institutions’ pharmacies. METHODS Starting from the applicable principles for long-term prescriptions of psychiatry， this study introduced the standardized assessment and precautions before issuing long-term prescriptions， the formulation and adjustment of the drug list， as well as the rational management of the long-term prescriptions. It also analyzed potential issues that may arise in the comprehensive management of long-term prescription medications and proposed corresponding countermeasures and suggestions. RESULTS & CONCLUSIONS Prior to initiating long-term prescriptions， a standardized assessment should be conducted on patients from the aspects of their psychiatric condition and long-term potential risk factors， pharmacological treatment plans and other non-pharmacological therapies， physical illnesses. Additionally， healthcare providers should fulfill their obligation to inform patients or their family members. The comprehensive management of long-term prescription medications should be jointly established and improved by multiple departments， and the formulation of drug catalogs should avoid including drugs with potential social harm or medication risks while complying with policy requirements. Furthermore， measures such as adding special identifiers to long-term prescriptions， providing patients with reminders about （No.YGLX202537） prescription expiration， or offering online consultations can also effectively enhance the rationality of medication use under long-term prescriptions. Currently， the implementation of long-term prescriptions in psychiatry remains challenged by inconsistencies in prescription duration， incomplete coverage of diagnostic categories， poor patient adherence， and the risk of deviation in clinical assessments. In this regard， measures such as collaborating with multiple departments to strengthen long-term prescription information management， providing matching pharmaceutical services， ensuring the quality and rationality of long-term prescription implementation， and using modern methods to screen high-risk patients can be taken to improve patient medication compliance and safety.

Objective To establish an expert consensus on the management of low anterior resection syndrome(LARS)in patients with rectal cancer post-surgery(hereinafter referred to as"consensus"),aiming to standardize the related work of medical institutions in the context of post-operative LARS.Methods A comprehensive search of domestic and international databases was conducted to collect guidelines,expert consensuses,systematic reviews,evidence summaries,and original research related to post-operative LARS in rectal cancer published from the establishment of the databases until August 2024.Based on clinical practice experience,a preliminary draft of the"consensus"was formed.From September to November 2024,22 experts were invited to participate in 2 rounds of expert consultations,during which the draft content was revised and improved,and the final version of the"consensus"was determined through expert validation.Results A total of 22 experts responded,achieving a response rate of 100％.The effective recovery rate of the consultation questionnaires in both rounds was 100％,with an expert authority coefficient of 0.89,a judgment coefficient of 0.97,and a familiarity degree of 0.84.The Kendall harmony coefficients for the 2 rounds of expert consultations were 0.122 and 0.136,respectively(P＜0.001).This consensus covers 5 main aspects:definition,assessment,prevention,treatment,and follow-up management of LARS.Conclusion This consensus demonstrates a high level of scientific rigor and can provide a strong reference for clinical nursing personnel in the specialized care of rectal cancer patients with post-operative LARS.

Objective:To investigate the clinicopathological and molecular genetic characteristics of intracranial mesenchymal tumors with FET::CREB fusion transcript.Methods:The clinical and imaging data of 6 cases of intracranial mesenchymal tumors with FET::CREB fusion from December 2018 to December 2023 were collected at the First Affiliated Hospital of Zhengzhou University. Their histological features, immunophenotype and molecular characteristics were analyzed.Results:Among the 6 patients, 4 were males and 2 were females, and the median age was 20 years. The clinical symptoms were increased intracranial pressure in 5 cases and epilepsy in 1 case. The lesion sites were cerebellum (2 cases), frontal lobe (2 cases), parietal lobe (1 case), and cranioorbital communication (1 case). The radiological features mainly showed solid or cystic components, with obvious annular enhancement on MRI. The histopathological features showed a wide spectrum of morphology, clear boundaries and fibrous pseudocapsule. The tumor cells were arranged in a lamellar or nodular pattern, and some in cord or loose network. The tumor cells were spindle, oval, epithelioid or stellate. The stroma was collagenous or mucin-rich, and accompanied by abundant lymphocytes and plasma cells infiltration. By immunohistochemical staining, desmin, CD99 and EMA were expressed in 6 cases, CD68 in 1 case, MUC4 in 1 case, synaptophysin in 2 cases, and ALK in 1 case. The Ki-67 proliferation index was between 1%-15%. Molecular analysis showed EWSR1::ATF1 fusion in 3 cases, EWSR1::CREB1 fusion in 2 cases, and EWSR1::CREM fusion in 1 case.Conclusions:Intracranial mesenchymal tumors with FET::CREB fusion are relatively rare and typically occur in children and younger adults. These tumors have a broad morphological spectrum and often express desmin, CD99 and EMA. The molecular characteristics are the gene fusions of FET family (mainly EWSR1, FUS) with CREB family transcription factors (ATF1, CREB1 or CREM). It is necessary to distinguish these tumors from meningiomas and solitary fibrous tumors, and the combination of immunohistochemical staining and molecular genetic testing can effectively help identify these tumors.

Antibiotic adjuvants offer a promising strategy for restoring antibiotic sensitivity, expanding antibacterial spectra, and reducing required dosages. Previously, compound 15 was identified as a potential adjuvant for Polymyxin B (PB) against multidrug-resistant (MDR) Pseudomonas aeruginosa DK2; however, its clinical utility was hindered by high cytotoxicity, uncertain in vivo efficacy, and an unclear synergetic mechanism. To address these challenges, we synthesized and evaluated a series of novel benzamide derivatives, with A22 emerging as a particularly promising candidate. A22 demonstrated potent synergistic activity to PB, minimal cytotoxicity, improved water solubility, and broad-spectrum synergism of polymyxins against various clinically isolated MDR Gram-negative strains. In vivo studies using Caenorhabditis elegans and mouse models further confirmed the efficacy of A22. Moreover, A22 effectively suppressed the development of PB resistance in Pseudomonas aeruginosa DK2. Mechanistic investigations revealed that A22 enhances polymyxins activity by inducing reactive oxygen species production, reducing ATP levels, increasing NOX activity, and inhibiting biofilm formation, leading to bacterial death. These findings position A22 as a highly promising candidate for the development of polymyxin adjuvants, offering a robust approach to combating MDR Gram-negative bacterial infections.

Advanced atherosclerosis is the major global cause of death, as featured by the aggregation of apoptotic cells (ACs) in necrotic cores. The defective efferocytosis and dysfunctional cholesterol efflux of macrophages are the main reasons for forming necrotic cores in advanced atherosclerosis. In this study, we constructed self-assembled procyanidins (PC) NPs for loading pitavastatin (Pita). The designed HA@PC@Pita NPs with hyaluronic acid (HA) modification combined the advantages of efferocytosis restoration of Pita and cholesterol efflux enhancement of PC. In vitro assay indicated that HA@PC@Pita NPs could induce M1/M2 repolarization and upregulate ERK5/Mertk expression to restore efferocytosis of macrophages. Simultaneously, HA@PC@Pita NPs notably promoted cholesterol efflux by promoting macrophage lipophagy, a selective autophagy of lipid droplets. In vivo study showed that HA@PC@Pita NPs cleared necrotic core and enhanced plaque stability in the ApoE ^-/- mice model with advanced atherosclerosis. Taken together, this study demonstrated the potential of HA@PC@Pita NPs for the treatment of advanced atherosclerosis.